- Tags: glaucoma
Pipeline
Nicox reports positive pre-NDA FDA meeting for IOP-lowering drop
NO-donating bimatoprost formulation remains on track for a summer 2026 new drug application submission.
Research
Dual GIP-GLP-1 RA shows superior efficacy in lowering POAG, OHT risk
Tirzepatide consistently reduced the risk of glaucomatous disease compared to GLP-1 RAs, even among high-risk patients.
Research
Iron overload may increase glaucoma risk
Study proposes that systemic iron dysregulation is a modifiable risk factor for glaucomatous disease.
Pipeline
First patient treated with Calibreye System in IDE glaucoma study
The ADAPT trial is evaluating Myra Vision’s next-gen aqueous shunt drainage device for optimizing IOP reduction in patients undergoing glaucoma surgery.
Research
Pseudoexfoliation glaucoma is most prevalent among Indigenous populations in the US
Study finds American Indian or Alaska Native patients are impacted by PXG and PG nearly threefold more than the general U.S. population.
Products
FDA approves Glaukos' iDose TR for repeat treatment labeling
Travoprost intracameral implant can now be re-administered using a repeat treatment protocol—enabling greater flexibility in glaucoma patient management.
Research
Beta-zone PPA may be major glaucoma disease marker for Black patients
Beta-zone PPA was linked with RNFL thinning, suggesting it may be a feature of glaucomatous change.
Pipeline
ViaLase's IDE trial treats first patient with novel femtosecond laser procedure
Pivotal study is comparing ViaLuxe Laser System with FLigHT as an incision-free canal procedure against SLT for POAG treatment.
Pipeline
Ocuvex resubmits FDA CRL for brimonidine tartrate 0.35% NDA
Shared by partner SPARC, update follows 2+ years after the 2022 submission of investigational OAG and OHT eye drop was rejected in July 2023.
Pipeline
SpyGlass Pharma reports long-term data on bimatoprost IOL system
Positive 36-month findings from an FIH trial and 3-month results from a phase 1/2 study support delivery of sustained IOP reduction and drop-free outcomes for OAG, OHT.
Products
VEO Ophthalmics and PeriVision launch VisionOne AI VF platform in the US
Exclusive partnership enables commercial market availability of the portable novel perimeter device, designed to perform visual field testing for glaucoma.
Products
Lumenis unveils updates to Digital Duet SLT+YAG platform
Version 2.0 builds on the advancements of the first and only all-in-one digital dual path system of its kind on the market.
Research
Physical activity tied to decreased glaucoma progression
Study highlights several ways that exercise may reduce the risk of progression in POAG patients.
Pipeline
FDA grants IDE approval for Avisi's glaucoma treatment device
IDE approval enables initiation of the open-label SAPPHIRE to evaluate the VisiPlate, an aqueous shunt designed to lower IOP among OAG patients.
Products
Iantrek launches AlloFlow Uveo in the US
Bio-interventional surgical implant targets the uveoscleral pathway to enhance aqueous flow (and lower IOP) in glaucoma patients.
Research
Childhood BMI may determine risk for POAG development
Regardless of childhood weight, low body size in adulthood consistently served as a risk factor for POAG.
Products
FDA approves FDC Limited's pilocarpine HCl ophthalmic solution
ANDA approval for generic eye drop extends to three concentrations: 1%, 2%, and 4%.
Products
FDA approves Amneal's bimatoprost 0.01% generic
Generic version of Allergan’s LUMIGAN is indicated for reducing elevated IOP in glaucoma and ocular hypertensive patients.
Research
Potential glaucoma prevention benefits linked to nitrate use
Oral nitrate use in patients with ischemic heart disease may have protective effects against glaucoma development.
Products